SAMSUNG BIOLOGICS CO.,LTD.
삼성바이오로직스(주)
207940CEO: 임존종보 (Rim John Chongbo)KOSPI
26.3Q Preliminary Results
PreliminaryRevenue
₩1.5T
QoQ +12.8%YoY +18.5%
Operating Profit
₩640.1B
QoQ +9.1%YoY +1.0%
Pre-tax Income
₩532.0B
QoQ -9.0%YoY -19.7%
Net Income
₩391.1B
QoQ -9.2%YoY -21.2%
Net Income (Owners)
₩391.1B
QoQ -9.2%YoY -21.2%
Disclosed 2026-10-21 · Preliminary figures may differ from final results
Quarterly Results
2026 Q2 (latest) · Revenue
₩1.3T
YoY
+2.4%
QoQ
+5.1%
Op. Margin
44.4%
Standalone quarterly figures · Tap a bar to view that quarter
1,514,000KRW
+19,000 (+1.27%)
Open
1,501,000
High
1,575,000
Low
1,497,000
Volume
10만
PER
42.17
PBR
8.44
Valuation
TTM as of 2026 Q2PER
44.90x
PBR
8.37x
PSR
15.40x
Market Cap
₩70.1T
5-Year Band
PERNow 44.90x· Below 5Y low
Low 69.82xMedian 92.10xHigh 219.08x
PBRNow 8.37x
Low 8.04xMedian 9.50xHigh 17.28x
| Year | Year-end Close | PER | PBR |
|---|---|---|---|
| 2025 | 1,681,952 | 69.82x | 10.44x |
| 2024 | 1,385,933 | 91.05x | 9.05x |
| 2023 | 1,109,914 | 92.10x | 8.04x |
| 2022 | 1,199,000 | 104.79x | 9.50x |
| 2021 | 1,303,319 | 219.08x | 17.28x |
Based on year-end closing prices, last 5 fiscal years
Insider Trading
BuySell
11월
12월
5월
8월
10월
11월
AI Financial Analysis
Check AI financial analysis in the app
AI comprehensively evaluates profitability, stability, growth, and more
Loading chart...
Dividends
No cash dividends in the last 6 years
Data source: Korea FSS DART (Electronic Disclosure System)